Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-03-29
2011-03-29
Fetterolf, Brandon J (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S255050, C514S262100, C514S359000, C514S404000, C514S638000, C514S248000
Reexamination Certificate
active
07915245
ABSTRACT:
This invention describes a series of methods and compositions for prevention and treatment of diseases such as cancer. One aspect of the invention describes small molecule-based drugs that can be used to bind to death receptors TRAIL-R1/DR4 and/or TRAIL-R2/DR5 and induce apoptosis in cancer cells, while sparing normal cells. The invention also describes TRAIL Death Receptor Agonists/Activators (DRAs) and their uses, such as the induction of apoptosis through caspase-8 and caspase-3 activation. The present invention also describes the methods of treating cancers, such as breast, prostate, colon, pancreatic, ovarian, lung, and brain cancers, leukemia, lymphoma, multiple myeloma, and mesothelioma, using DRAs either as single-agent treatments, or in combination with other therapies.
REFERENCES:
patent: 4325959 (1982-04-01), Matthews
patent: 6897240 (2005-05-01), Cohen et al.
patent: 7078493 (2006-07-01), Greene et al.
patent: 7109298 (2006-09-01), Browning et al.
patent: 7115717 (2006-10-01), Mori et al.
patent: 7164004 (2007-01-01), Ruben et al.
patent: 2002/0091148 (2002-07-01), BaMaung et al.
patent: 2004/0133012 (2004-07-01), Brown
patent: 1 693 369 (2006-08-01), None
patent: WO 01/81315 (2001-11-01), None
patent: WO 02/079377 (2002-10-01), None
patent: WO 03/073999 (2003-09-01), None
patent: WO 03/084475 (2003-10-01), None
patent: WO 2004/093803 (2004-11-01), None
patent: WO 2005/007141 (2005-01-01), None
patent: WO 2005/070024 (2005-08-01), None
patent: WO 2006/044402 (2006-04-01), None
patent: WO 2006/105237 (2006-10-01), None
Rosenberg. Immunotherapy and Gene Therapy of Cancer. Cancer Research, 51, 5074s-5079s, 1991.
Nillson et al. Phase II study of single agent gemcitabine in patients with hormone refractory prostate cancer. Journal of CAncer, 2004 ASCO Annual Meetings Proceedings (Post-Meeting Edition). vol. 22, No. 14S (Jul. 15 Supplement): 4705.
Goodman et al. [Editors] “Chapter 198: Principles of Cancer Therapy.” Cecil's Textbook of Medicine (Twenty-First Edition, vol. 1). W.B. Saunders Company, 2000. pp. 1060-1074.
International Search Report and Written Opinion issued in Application No. PCT/US2007/080211, dated Jan. 5, 2009.
“Benzoic acid, 3-[ [ (2, 3-dibromo-5-ethoxy-6-hydroxyphenyl)methylene]amino]-,” Database Chemcats Chemical Abstract, Sep. 6, 2007.
Bakhite et al., “Synthesis and some reactions of new Thieno[2, 3-c]pyridazine derivatives,”Bull. Korean Chem. Soc., 23:1715-1718, 2002.
Li et al., “A small molecule Smac minic potentiates TRAIL- and TNFalpha—mediated cell death,”Science, 305:1471-1474, 2004.
Radwan, “Synthesis and reactions of some new heterocyclic compounds containing thieno {2, 3-c]pyridazine moiety,” Chemical Abstract accession No. 2000:813677, 2000.
Alnemri et al., “Human ICE/CED-3 protease nomenclature,”Cell, 87:171, 1996.
Ashkenazi and Dixit, “Death receptors: signaling and modulation,”Science, 281:1305-1308, 1998.
Ashkenazi et al., “Apoptosis control by death and decoy receptors,”Curr. Opin. Cell. Biol., 11:255-260, 1999.
Ashkenzai et al., “Safety and antitumor activity of recombinant soluble Apo2 ligand,”J. Clin. Invest., 104:155-162, 1999.
Butler et al., “Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo,”Cancer Res.,60: 5165-5170, 2000.
Cal et al., “Resveratrol and cancer: chemoprevention, apoptosis, and chemo-immunosensitizing activities,”Curr. Med. Chem. Anti-Cancer Agents, 3:77-93(Abstract), 2003.
Chen et al., “Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer,” Oncogene, 20:6073-6083, 2001.
Chinnaiyan et al., “Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy,”Proc. Natl. Acad. Sci. USA, 97:1754-1759, 2000.
Coffey et al., “The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid,”Cancer Res., 61:3591-3594, 2001.
Coffey et al., “Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro,”Med. Pediatr. Oncol., 35:577-581, 2000.
Cress and Seto, “Histone deacetylases, transcriptional control, and cancer,”J. Cell. Physiol., 184:1-16, 2000.
Culver et al., “In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors,”Science, 256:1550-2(Abstract), 1992.
Deckert and Struhl, “Histone acetylation at promoters is differentially affected by specific activators and repressors,”Mol. Cell. Biol., 21:2726-2735, 2001.
Deeb et al., “Curcumin (diferuloyl-methane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells,”Mol. Cancer Ther., 2:95-103, 2003.
Degli-Esposti et al., “The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain,”Immunity, 7:813-820, 1997.
Degli-Esposti et al., “Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family,”J. Exp. Med., 186:1165-1170, 1997.
Desagher and Martinou, “Mitochondria as the central control point of apoptosis,”Trends Cell. Bio., 10:369-377, 2000.
Droin et al., “Egr family members regulate nonlymphoid expression of Fas ligand, TRAIL, and tumor necrosis factor during immune responses,”Mol. Cell. Biol., 23:7638-7647, 2003.
Du et al., “Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition,”Cell, 102:33-42, 2000.
Emery et al., “Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL,”J. Biol. Chem., 273:14363-14367, 1998.
French and Tschopp, “Protein-based therapeutic approaches targeting death receptors,”Cell Death Differ., 10:117-123, 2003.
Fulda and Debatin, “Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol,”Cancer Res., 64:337-346, 2004.
Fulda and Debatin, “Apoptosis pathways: turned on their heads?,”Drug Resist., 6:1-3, 2003.
Gibson et al., “Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL,”Mol. Cell. Biol., 20:205-212, 2000.
Gliniak and Le, “Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11,”Cancer Res., 59:6153-6158, 1999.
Gong et al., “Ionizing radiation-induced, Bax-mediated cell death is dependent on activation of cysteine and serine proteases,”Cell Growth Differ., 10:491-502, 1999.
Gopee et al., “Sodium selenite-induced apoptosis in murine B-lymphoma cells is associated with inhibition of protein kinase C-delta, nuclear factor kappaB, and inhibitor of apoptosis protein,”Toxicol. Sci. 78:204-214, 2004.
Gray and Teh, “Histone acetylation/deacetylation and cancer: an “open” and “shut” case?,”Curr. Mol. Med., 1:401-29(Abstract), 2001.
Green and Reed, “Mitochondria and apoptosis,”Science, 281:1309-1312, 1998.
Green, “Apoptotic pathways: the roads to ruin,”Cell, 94:695-698, 1998.
Gregory et al., “Histone acetylation and chromatin remodeling,”Exp. Cell Res., 265:195-202, 2001.
Griffith et al., “Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL,”J. Exp. Med., 189:1343-1354, 1999.
Grinberg et al., “tBID Homooligomerizes in the mitochondrial membrane to induce apoptosis,”J. Biol. Chem., 277:12237-12245, 2002.
Gross et al., “Caspase cleaved BID targets mitochond
Mackerell, Jr. Alexander D.
Shankar Sharmila
Srivastava Rakesh
Fetterolf Brandon J
Fulbright & Jaworski LLP
Pagonakis Anna
The Board of Regents of the University of Texas System
LandOfFree
Methods and compositions of trail-death receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions of trail-death receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions of trail-death receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2764944